Strategic Priority 1:
Strengthening Pediatric Rare Disease Clinical Trial Capacity and Advanced Therapy Medicinal Product Readiness

SCROLL DOWN

Goal

To equip Canadian pediatric research institutions and affiliated hospitals to attract, develop, and conduct high-quality, innovative pediatric rare disease clinical trials, especially but not exclusively to Advanced Therapy Medicinal Products (ATMP); and to enhance readiness to administer ATMPs within a research and clinical setting. This is broken down into 5 key initiatives:

  1. Academic Leadership, Guidance and Training

  2. ATMP Standard Operating Procedures (SOPs) Development and Training

  3. Network of Pediatric ATMP Clinical Trials and Delivery-Ready Units

  4. Innovative Models

  5. Centralized Supports for Pediatric Rare Disease Clinical Trials (PRDCTs)

Scroll through below to find out more about these initiatives